Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-18T16:05:55.007Z Has data issue: false hasContentIssue false
  • English
  • Français

Lo viejo frente a lo nuevo: sopesar los datos entre los antipsicóticos de primera y segunda generación

Published online by Cambridge University Press:  12 May 2020

John M. Davis  and
Nancy Chen
John M. Davis
Affiliation:
Departamento de Psiquiatría (M/C 912), Universidad de Illinois en Chicago, Centro de Investigación Psiquiátrica de la Universidad de Maryland, 1601 W. Taylor Street, Chicago, IL, EE. UU.
Nancy Chen
Affiliation:
Departamento de Psiquiatría (M/C 912), Universidad de Illinois en Chicago, Centro de Investigación Psiquiátrica de la Universidad de Maryland, 1601 W. Taylor Street, Chicago, IL, EE. UU.
Get access

Resumen

En nuestra opinión, la mejor guía para prescribir antipsicóticos es la experiencia del profesional clínico con sus pacientes y en particular, el paciente al que se está tratando. Si el tratamiento funciona, aférrate a el. Pensamos que es importante también que el profesional clínico considere los datos de los estudios doble ciego de asignación aleatoria bien controlados porque, en la “medicina basada en los datos”, los sesgos tanto conocidos como desconocidos se controlan por el diseño ciego y la distribución al azar. El próposito de este artículo es resumir y analizar los datos sobre eficacia. La elección de antipsicótico, en nuestra opinión, es probablemente la decisión más importante que el profesional clínico toma a favor del paciente psicótico. Esto implica la elección del medicamento, sus dosis y equilibrar la eficacia, los efectos secundarios y el coste.

Keywords

AntipsicóticosMeta-análisisEficaciaDosis
Type
Artículo original
Information
European Psychiatry (Ed. Española) , Volume 12 , Issue 4 , May 2005 , pp. 223 - 230
Copyright
Copyright © European Psychiatric Association 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Davis JM, Chen N. Old versus new: weighing the evidence between the first and second-generation antipsychotics. Eur Psychiatry 2005;20:7-14.

References

Bibliografía

[1]Allison, DBMentore, JLHeo, MChandler, LPCappelleri, JCInfante, MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthosis. Am J Psychiatry 1999; 156: 1686-96.Google Scholar
[2]Colonna, LSaleem, PDondey-Nouvel, LRein, W. Long-term safety and etficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 2000; 15: 13- 22.CrossRefGoogle ScholarPubMed
[3] Comprehensive meta-analysis. a Computer program for research synthesis [Computer program], Englewood, NJ: Biostat; 1999.Google Scholar
[4]Correll, CULeucht, SKane, JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414-25.CrossRefGoogle ScholarPubMed
[5]Csernansky, JGMahmoud, RBrenne, R, Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New Engl J Med 2002; 346: 16–22.CrossRefGoogle ScholarPubMed
[6]Davis, JMChen, N. Choice of maintenance medication for schizophrenia. J Clin Psychiatry 2003; 64: S24-33.Google Scholar
[7]Davis, JMChen, NGlick, ID. A meta-analysis of the etficacy of second generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-64.CrossRefGoogle ScholarPubMed
[8]Davis, JMChen, N. Dose-response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004; 24: 192–208.CrossRefGoogle ScholarPubMed
[9]Duggan, LFenton, MDardennes, RMEl-Dosoky, AIndran, S. Olanzapine for schizophrenia. In: Cochrane review on CD-ROM. Oxford, UK: Cochrane Library (Update Soflware, issue 2); 2002.Google Scholar
[10]Fenton, MMorris, SDe-Silva, PBagnall, ACooper, SJGammelin, G, et al. Zotepine for schizophrenia. Cochrane Database Syst. Rev 2002; 2:CD001948.Google Scholar
[11]Geddes, JFreemantle, NHarrison, PBebbington, P, The National Schizophrenia Guideline Development Group. Atypical antipsychotics in the treatment of schizophrenia systematic OverView and metaregression analysis. BMJ 2000; 321: 1371-6.CrossRefGoogle Scholar
[12]Halbreich, UKinon, BJGilmore, JAKahn, LS. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003; 28: S53-67.CrossRefGoogle ScholarPubMed
[13]Hamner, M. The effects of atypical antipsychotics on serum, prolactin levels. Ann Clin Psychiatry 2002; 14: 163-73.CrossRefGoogle ScholarPubMed
[14]Kennedy, ESong, FHunter, RClarke, AGilbody, S. Rispendone versus typical antipsychotic medication for schizophrenia. In: Cochrane review on CD-ROM. Oxford, UK: Cochrane Library (Update Software, issue 2); 2002.Google Scholar
[15]Leucht, SPitschel-Walz, GAbraham, DKissling, W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled triais. Schizophr Res 1999; 35: 51–68.CrossRefGoogle Scholar
[16]Leucht, SPitschel-Walz, GEngel, RRKissling, W. Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled triais. Am J Psychiatry 2002; 159: 180-90.CrossRefGoogle Scholar
[17]Leucht, SWahlbeck, KHamann, JKissling, W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581-9.CrossRefGoogle ScholarPubMed
[18]Leucht, SWagenpfeil, SHamann, JKissling, W. Amisulpride is an “atypical” antipsychotic associated with low weight gain. Psychopharmacology (Berl) 2004; 173: 112-5,CrossRefGoogle ScholarPubMed
[19]May, PRTuma, AHYale, CPotepan, PDixon, WJ. Schizophrenia— a follow-up study of results of treatment. Arch Gen Psychiatry 1976; 33: 481-6.CrossRefGoogle ScholarPubMed
[20] MetaWin. Statistical software for meta-analysis [Computer program]. Version 2.0. Sunderlund, MA: Sinauer Associates; 2000.Google Scholar
[21] SAS Institute Inc, Wang, MCBushman, BJ. Integrating results through meta-analytic review using SAS software. Cary, NC: SAS Institute Inc.; 1999.Google Scholar
[22]Srisurapanont, MDisayavanish, CTaimkaew, K. Quetiapine for schizophrenia. In: Cochrane review on CD-ROM. Oxford, UK: Cochrane Library (Update Software, issue 2); 2002.Google Scholar
[23]Wahlbeck, KCheine, MEssali, MA. Clozapine versus typical neuroleptic medication for schizophrenia. In: Cochrane review on CDROM. Oxford, UK: Cochrane Library (Update Software, issue 2); 2002.Google Scholar